GSK and Galapagos go separate ways on once-hyped anti-infective alliance
This article was originally published in Scrip
It emerged at an R&D update provided by the Belgian biotech firm Galapagos this week that the potentially high-value anti-infectives alliance it established with GlaxoSmithKline in 2007 was dissolved last year. Galapagos took back rights to the antibacterial programmes and GSK retained those for the viral programmes in a split which Galapagos CEO Onno van de Stolpe said was prompted by Galapagos deciding that the costs of the alliance were unsustainable on its part.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.